[ad_1]
Industry and Technology Minister Mustafa Varank on the nation’s groundbreaking vaccine studies, “If all stages are successfully completed, we will have a candidate vaccine with a capacity of 50 million doses by the end of the year.” saying.
Minister Varank answered questions from members of the press on Parliament’s agenda. Turkey’s groundbreaking vaccine trials from being the fourth last vaccine candidate in the world to human trials and the World Health Organization (WHO) called for evaluation of the achievement of entering the Varank list, “There is a technology we call VLP technology. It was the fourth vaccine in this area. Or in many different technologies in the world, the World There are studies of vaccines accepted by the Health Organization. We correct the misunderstanding there. ” speak.
Noting that this is a groundbreaking vaccine study, Varank said: “It is trying to create antibodies with a structure that resembles a virus. This is just the expression. But our vaccine is a different vaccine technology in terms of that both are new technology and being a protein-based vaccine targeting all 4 regions of the virus. Of course, we have high hopes for our vaccine. Our teachers have been doing this for a year with superhuman effort. ” used expressions.
Stating that the human studies began on Saturday morning, Varank said that the processes are not easy and that there is no possibility of completing the Phase 1 study before 2 months.
Stating that the facilities that will produce these vaccines are also ready, Varank said that “if all stages are completed successfully, we will have a candidate vaccine with a capacity of 50 million doses by the end of the year.” saying.
Mustafa Varank stated that he will also participate as a volunteer in the second group of vaccinations.
“All authority in the Turkish Pharmaceutical Products and Medical Devices Agency”
Noting that it is not possible to complete Phase 1 and Phase 2 studies before 4 months, Varank noted that the processes, including all testing and vaccinating people, are lengthy.
Recalling that it was decided to increase the number of centers where first-stage clinical studies were conducted from 9 to 20 at the Evaluation Meeting held under the chairmanship of Vice President Fuat Oktay, Varank said: “To accelerate these processes, our Ministry of Health will increase the number of clinical studies to 20. Therefore, it will be much easier to carry out these studies in the coming periods. ” speak.
Varank, Minister of Industry and Technology, said of the nasal vaccine study: “This is a type of protein-based vaccine. This is one of the innovative types of vaccine in the world. This is a vaccine study to be administered through the nose. METU professor is leading this., experimental animals, complement other efforts. Turkey made its request to the Agency for Pharmaceutical Products and Medical Devices. After the files are evaluated, they can start work immediately if they receive approval. They will begin human experimentation. “he gave the answer.
Recalling that the Minister of Health, Fahrettin Koca, recommended the Ankara City Hospital to those who will carry out the study, Varank said that they will establish a clinical center and carry out their studies there.
Stating that the nasal vaccine is also an innovative type of vaccine and does not have much application in the world, Varank said: “But the first results, laboratory experiments, animal experiments from our friends seem quite successful. I hope the clinical study be successful. ” . ” saying.
Varank the questions that the study of how it began, “All authority in Turkey Pharmaceuticals and medical devices of the institution here. Its in this process, not once, 3, for approval four times. Plant approval, has approval of human trials. So here they are subject to them because all the powers they process are working. ” gave the answer.
“You can get results by changing the design”
On the reminder of mutated viruses, Varank said: “Both the nasal vaccine and the VLP vaccine are types of vaccines that can be designed very easily for mutations. The design is changed. Therefore, these processes are not repeated. You can only get results by changing the design. ” speak.
Explaining that they want to use the VLP vaccine against the British mutation in the second phase, Varank said: “They made that design at this time. They are currently doing their tests in the laboratory. A characteristic of these vaccines is that they can change their design very quickly against mutations “. used expressions.
By stating that the issue of vaccines is on everyone’s agenda, Varank drew attention to the fact that underdeveloped countries almost never have access to vaccines.
Stating that there are different demands from different countries, Varank said, “There are countries that say ‘Help us’ in purchasing vaccines and they also want to act together in these studies. For example, there are countries that offer to carry out Phase-3 experiments together. Our processes will be shortened and its reputation will increase as it will be an international study. We could also have the opportunity to give priority to those countries in the supply of vaccines. There is interest from abroad. ” saying.
Expressing that he is waiting to volunteer, Varank said that these vaccines do not have 100% protection and there is a risk of transmission when vaccinated.
In his presentation at the last cabinet meeting of the Minister of Health, Fahrettin Koca, Varank explained that he showed a decrease in the number of intubated and seriously ill patients in this age group since the vaccines over 65 years old were completed, “This means that vaccines are occupational. ” saying.
Emphasizing that Health Minister Koca has made great efforts to acquire vaccines, Varank said that all people who reach the age group should be vaccinated.
Stating that it is not possible for them to accept opposition to vaccination, Varank stressed that the only way to combat this disease is by getting vaccinated.
Stating that Turkey Varank takes place among the most advanced countries in the world in vaccination of Turkey, “especially in the smaller countries of the European Union it would not be wrong to say that there is almost no vaccination yet. Turkey is carrying out these processes successfully. “. speak.
On the question of the cost of the vaccine, Varank said: “It is not correct to speak of a number as of today. Because capacity is important here. How much will be produced, how much will it take to develop the necessary infrastructure here.” It is not correct to talk about the cost without calculating them all. “
Mustafa Varank, in a question about whether the vaccines will be sold in pharmacies, “Whatever the rules of our Ministry of Health, they will follow them. Currently, the vaccine is not sold in the pharmacy. It will be a different application. This needs to be evaluated. like a normal vaccine. ” used the expression.
